NAMPT and myeloid sarcoma: As regards visfatin, this is partly in line with a recent study by Mirzaei K et al [17] in which observed that its level tended to be higher, albeit not significantly in patients with RR-MS as compared with those in SP-MS and PP-MS as a single group.